Nexentis 1-for-5 Reverse Split Sets Nov 9 Nasdaq Open

Nexentis Technologies Inc. (NASDAQ: NXTS) announced on November 5, 2026 that its Board of Directors approved a 1-for-5 reverse stock split, scheduled to take effect for Nasdaq purposes on November 9, 2026. Outstanding shares fall from roughly 2.9 million to about 600 thousand, and the stock trades under a new CUSIP, 80512Q709, while keeping the NXTS symbol on the Nasdaq Capital Market. The company said the move is intended to lift its per-share price and bid price back into compliance with continued listing requirements.

Context — Why Is Nexentis Splitting Its Stock Now?

The report ties the split directly to a stockholder authorization granted months earlier. At a Special Meeting held April 30, 2026, holders approved a proposal letting the Board effect one or more reverse splits at any ratio between 1-for-2 and 1-for-500. The company said the purpose was to raise the per-share price and bid price of its common stock to regain compliance with Nasdaq's continued listing requirements and to make the shares more attractive to certain institutional investors, which it said would provide for a stronger investor base.

That authorization set the outer bounds of what the Board could do. The chosen 1-for-5 ratio sits near the conservative end of the approved range, well short of the 1-for-500 maximum. Nexentis did not disclose in this report the specific Nasdaq deficiency notice, the bid price threshold it breached, or the compliance deadline it faces.

What changed to trigger the action now is the approach of Nasdaq's compliance calendar. The company frames the split as a means to an end — a higher quoted price — rather than a change to the underlying business. Nexentis owns 100% of MitoCareX Bio Ltd., a drug-discovery company, and separately runs an investment strategy focused on European renewable energy assets under an RTB (Ready to Build) model.

The macro backdrop is not cited in the report. No rate, yield or index level is given, and none should be read into the decision. The catalyst chain here is internal: stockholder approval in April, Board action in November, effectiveness on the Nasdaq open of November 9.

Data — What the Numbers Show

The scale of the change is mechanical and quantifiable. Before the split, Nexentis had approximately 2.9 million shares outstanding. After effectiveness, that figure becomes approximately 600 thousand. Every five shares convert into one, with a proportionate adjustment to the exercise price and share count of all outstanding options and warrants.

Metric	Before Split	After Split
Shares outstanding	~2.9 million	~600 thousand
Conversion ratio	5 shares	1 share
Authorized shares	Unchanged	Unchanged
Ticker	NXTS	NXTS
CUSIP	Prior	80512Q709

Two details matter for holders. First, the number of authorized shares does not change — only the count of issued and outstanding stock shrinks. Second, no fractional shares will be issued. A holder whose pre-split position is not evenly divisible by five receives an additional fraction of a share, automatically rounded up to the next whole share. That rounding mechanism means small holders can see their effective ownership percentage tick marginally higher.

The report gives no pre-split share price, no post-split implied price, no market capitalization and no peer comparison. Those figures are absent, and any level cited for NXTS would have to come from live market data rather than this announcement.

Administratively, registered holders in book-entry form or through a bank, broker or nominee need take no action. Holders of physical certificates must work with the transfer agent, Securities Transfer Corporation, which will send exchange instructions and can be reached at (469) 633-0101.

Analysis — What a 1-for-5 Split Means for NXTS Holders

A reverse split is arithmetic, not value creation. The company's own framing is telling: the stated goals are a higher per-share price, a higher bid price and a broader institutional holder base. None of those changes the economics of the drug-discovery pipeline at MitoCareX Bio or the four solar projects Nexentis describes as its lead investments across three European Union countries, all introduced by Solterra Renewable Energy Ltd., a wholly owned subsidiary of Solterra Energy Ltd.

The counter-argument is straightforward. Reverse splits are frequently read by the market as a signal of distress rather than a fix, because they are most often used by issuers that have already lost a listing standard. Nexentis does not disclose the size of the deficiency or how much headroom the new price creates. A 1-for-5 ratio on a 2.9 million share count implies a very small float, and thin floats can produce volatile post-split trading independent of fundamentals.

The second-order effects run to the sector rather than to individual names. Micro-cap biotech and small-cap renewable energy developers both trade on listing-standard risk, and both are exposed when a peer executes a split to stay on an exchange. Nexentis sits at the intersection of those two categories, which narrows the universe of comparable issuers.

On positioning, the report gives no short interest, no institutional ownership and no analyst coverage. What it does say is that management believes a higher quoted price draws institutional capital. Whether that flow materializes is the open question, and the report offers no evidence either way.

Outlook — What to Watch After November 9

The first checkpoint is the Nasdaq open on November 9, 2026, when NXTS begins trading split-adjusted under CUSIP 80512Q709. That is the date the company gives for effectiveness, and it is the first session in which the new price and bid will be visible.

The second is the compliance clock. Nexentis has not stated the deadline by which it must hold a bid above Nasdaq's minimum threshold, nor the length of any cure period granted. Until the company discloses that, the market cannot price the odds of a delisting notice.

The third is the proxy trail. The company points readers to its definitive proxy statement filed with the SEC on March 12, 2026, which carries the full terms of the authorization. Any further detail on the ratio rationale would surface there or in subsequent filings, including the Form 10-K filed March 31, 2026.

No support or resistance levels are named in the report, and no moving averages are cited. There is no price level to anchor on from this disclosure alone.

Frequently Asked Questions

What does a 1-for-5 reverse stock split mean for Nexentis shareholders?

Every five shares of Nexentis common stock convert into one share when the split takes effect on November 9, 2026. The total share count drops from roughly 2.9 million to about 600 thousand, while authorized shares stay the same. Holders end up with fewer shares at a proportionally higher price, so the dollar value of the position is unchanged at the moment of conversion. Option and warrant terms adjust proportionately.

Will Nexentis shareholders need to do anything to receive new shares?

Most holders do not. The company said stockholders holding in book-entry form or through a bank, broker or other nominee need take no action. Only holders of physical stock certificates must act, and the transfer agent, Securities Transfer Corporation, will send instructions for exchanging those certificates for new ones representing the post-split share count. The agent can be reached at (469) 633-0101.

Why is Nexentis doing a reverse split instead of a regular stock split?

A reverse split raises the per-share price and bid price rather than lowering them. Nexentis said the goal is to regain compliance with Nasdaq's continued listing requirements and to make the common stock more attractive to certain institutional investors. Stockholders authorized the Board at the April 30, 2026 Special Meeting to act at any ratio from 1-for-2 to 1-for-500; the Board chose 1-for-5.

Bottom Line

Nexentis is compressing 2.9 million shares into roughly 600 thousand to clear a Nasdaq bid-price hurdle, with the split-adjusted stock trading November 9 under CUSIP 80512Q709.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.